Premium
Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low‐dose cyclosporine A
Author(s) -
Pape Lars,
Ahlenstiel Thurid,
Ehrich Jochen H. H.,
Offner Gisela
Publication year - 2007
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/j.1399-3046.2006.00651.x
Subject(s) - medicine , urology , renal function , immunosuppression , everolimus , creatinine , nephropathy , prednisolone , gastroenterology , endocrinology , diabetes mellitus
Until now there have been no good therapeutic options in children with biopsy‐proven transplant nephropathy (TN) and loss of glomerular filtration rate (GFR) while receiving cyclosporine A (CsA), mycophenolate mofetil (MMF) and prednisolone (Pred). In 13 kidney transplanted children (mean age 13 yr, SD 4) with CsA/MMF/Pred immunosuppression, renal biopsy revealed significant TN. MMF was discontinued, CsA dose was reduced to 50% and Everolimus was started (1.6 mg/m 2 /day). Pred was stopped in 10 of 13 patients. The mean GFR was 55 mL/min/1.73 m 2 (SD 24) one yr before switch, 45 mL/min/1.73 m 2 (SD 16, p < 0.05) at the time of switch and 47 mL/min/1.73 m 2 (SD 18, p < 0.05) 12 months later. There were no severe side‐effects or acute rejections. Lactate dehydrogenase, cholesterol, creatine kinase, and U‐albumin/creatinine ratio did not increase significantly. After six months, the mean certican‐C0 level was 4.0 μ g/L (SD 1.5) and mean CsA‐C0 level was 52 ng/mL (SD 23). The GFR of transplanted kidneys in children with TN improved by changing immunosuppression from CsA/MMF/Pred to everolimus and low‐dose CsA.